Lupin is currently trading at Rs. 992.95, up by 5.30 points or 0.54% from its previous closing of Rs. 987.65 on the BSE.
The scrip opened at Rs. 990.00 and has touched a high and low of Rs. 999.00 and Rs. 990.00 respectively. So far 8406 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1590.00 on 09-Sep-2016 and a 52 week low of Rs. 920.00 on 21-Aug-2017.
Last one week high and low of the scrip stood at Rs. 1008.90 and Rs. 942.10 respectively. The current market cap of the company is Rs. 44953.82 crore.
The promoters holding in the company stood at 46.70%, while institutions and non-institutions held 40.66% and 12.63% respectively.
Lupin's Japanese subsidiary Kyowa Pharmaceutical Industry Co., has listed the NHI (National Health Insurance) drug price for Bipresso (generic name: Quetiapine Fumarate) extended release 50mg and 150 mg tablets for the treatment of depressive symptoms associated with bipolar disorder. NHI drug price are listed at 71.00 Yen per 50mg tablet and 188.60 Yen per 150mg tablet.
Astellas Pharma Inc. obtained approval for Bipresso Extended Release Tablets on July 3, 2017. Bipresso Extended Release Tablets contains the active ingredient quetiapine fumarate and is an extended-release tablet to be taken orally once a day. Based on the agreement between Astellas and Kyowa made in February 2017, Kyowa will distribute, sell and promote Bipresso Extended-Release Tablets exclusively in Japan.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.